<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8439">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833976</url>
  </required_header>
  <id_info>
    <org_study_id>2008-P-002219</org_study_id>
    <nct_id>NCT00833976</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia</brief_title>
  <official_title>Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia
      in subjects who have been on an atypical (second-generation) antipsychotic medication. The
      investigators hypotheses are that patients who receive Lovaza will experience a significant
      decrease in triglycerides from baseline. Secondary hypotheses include: Patients will
      experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia
      in subjects who have been on an atypical (second generation) antipsychotic medication.
      Eligible subjects include men and women, ages 18-75, who have been taking an atypical
      antipsychotic for at least three months prior to enrollment. Atypical antipsychotics
      include: clozapine (Clozaril), olanzapine (Zyprexa), risperidone (Risperdal), aripiprazole
      (Abilify), ziprasidone (Geodon), quetiapine (Seroquel), paliperidone (Invega), asenapine
      (Saphris), iloperidone (Fanapt), and lurasidone (Latuda). Eligible subjects must also have
      serum triglycerides &gt;200 mg/dl or high cholesterol &gt;250 mg/dl at baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Triglycerides From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Total Cholesterol</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Lovaza</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>High Triglycerides</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>open-label Lovaza (omega-3 fatty acids)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4g per day (4g once a day or 2g two times a day) for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>4 grams per day</description>
    <arm_group_label>open-label Lovaza (omega-3 fatty acids)</arm_group_label>
    <other_name>Omega 3 Fatty Acids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or male patients, 18-75 years of age.

          2. Serum triglycerides &gt;200 mg/dl or high cholesterol &gt;250 mg/dl

          3. Current use of an atypical (second-generation) antipsychotic medication - including
             clozapine (Clozaril), olanzapine (Zyprexa), risperidone (Risperdal), aripiprazole
             (Abilify), ziprasidone (Geodon), quetiapine (Seroquel), paliperidone (Invega) - for
             at least three months

        Exclusion Criteria:

          1. Current use of triglyceride or cholesterol-lowering medication other than a statin

          2. Current use of omega-3 fatty acid supplement

          3. Intake of fish more than twice per week

          4. Currently pregnant, or breastfeeding

          5. Known hypersensitivity or allergy to omega-3 fatty acids (or any fish allergies)

          6. Current use of anticoagulant medication, except for 1 baby aspirin/day - 81mg
             (coumadin, heparin, Plavix. etc).

          7. Consumption of alcohol greater than two drinks per day or active substance abuse

          8. Any medical condition that would make participation in the study unsafe, as
             determined by investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene P Freeman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.womensmentalhealth.org</url>
    <description>Massachusetts General Hospital's Center for Women's Mental Health</description>
  </link>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 14, 2016</lastchanged_date>
  <firstreceived_date>January 29, 2009</firstreceived_date>
  <firstreceived_results_date>April 14, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Marlene P. Freeman, MD</investigator_full_name>
    <investigator_title>Director of Clinical Services, MGH Center for Women's Mental Health</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open-label Lovaza (Omega-3 Fatty Acids)</title>
          <description>4g per day (4g once a day or 2g two times a day) for 16 weeks
Lovaza: 4 grams per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open-label Lovaza (Omega-3 Fatty Acids)</title>
          <description>4g per day (4g once a day or 2g two times a day) for 16 weeks
Lovaza: 4 grams per day</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48" spread="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Triglycerides From Baseline to 16 Weeks</title>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Open-label Lovaza (Omega-3 Fatty Acids)</title>
            <description>4g per day (4g once a day or 2g two times a day) for 16 weeks
Lovaza: 4 grams per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Triglycerides From Baseline to 16 Weeks</title>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62" spread="97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Total Cholesterol</title>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Lovaza</title>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open-label Lovaza (Omega-3 Fatty Acids)</title>
          <description>4g per day (4g once a day or 2g two times a day) for 16 weeks
Lovaza: 4 grams per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Unpleasant taste</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gassy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Compulsive eating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal potassium levels</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abnormal levels of sodium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marlene Freeman, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-643-6403</phone>
      <email>mfreeman@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
